Eagle Pharmaceuticals (EGRX) Lowered to Hold at BidaskClub

BidaskClub lowered shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a buy rating to a hold rating in a research note released on Thursday.

Other equities research analysts have also issued reports about the company. Piper Jaffray Companies restated a buy rating and set a $75.00 price objective on shares of Eagle Pharmaceuticals in a research report on Friday, October 27th. ValuEngine upgraded Eagle Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, October 2nd. Zacks Investment Research lowered Eagle Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Tuesday, January 9th. Royal Bank of Canada restated an outperform rating and set a $75.00 price objective (down from $81.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 9th. Finally, Mizuho restated a sell rating and set a $37.00 price objective on shares of Eagle Pharmaceuticals in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $62.33.

Eagle Pharmaceuticals (NASDAQ EGRX) traded down $0.08 during trading hours on Thursday, hitting $58.84. The company had a trading volume of 111,488 shares, compared to its average volume of 166,918. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.30 and a quick ratio of 5.15. Eagle Pharmaceuticals has a fifty-two week low of $45.05 and a fifty-two week high of $97.15. The firm has a market cap of $879.18, a price-to-earnings ratio of 9.49 and a beta of 1.24.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.50. Eagle Pharmaceuticals had a return on equity of 62.60% and a net margin of 36.95%. analysts anticipate that Eagle Pharmaceuticals will post 2.23 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Municipal Employees Retirement System of Michigan raised its stake in shares of Eagle Pharmaceuticals by 68.1% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock worth $191,000 after purchasing an additional 1,300 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Eagle Pharmaceuticals by 58.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock worth $194,000 after purchasing an additional 908 shares in the last quarter. Schroder Investment Management Group purchased a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth about $219,000. Foundry Partners LLC purchased a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth about $224,000. Finally, Kopp Investment Advisors LLC raised its stake in shares of Eagle Pharmaceuticals by 0.3% during the 2nd quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock worth $241,000 after purchasing an additional 10 shares in the last quarter.

WARNING: “Eagle Pharmaceuticals (EGRX) Lowered to Hold at BidaskClub” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://stocknewstimes.com/2018/01/20/eagle-pharmaceuticals-egrx-lowered-to-hold-at-bidaskclub.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply